Filing Flows › Sanara MedTech (SMTI) › Q2 2026 › vs Q2 2025
Sanara MedTech (SMTI) Q2 2026 vs Q2 2025 (year over year)
Sanara MedTech's revenue rose $2.3M (+9%) from $25.8M in Q2 2025 to $28.1M in Q2 2026. The biggest changes: Soft Tissue Repair Products +$2.6M (+11%); Bone Fusion Products −$249K (-8%).
Sanara MedTech, Q2 2026: revenue $28.1M (+9% year over year), operating margin 6.3%, net loss $453K, operating cash flow $2.0M. The chart draws each line against Q2 2025, the increases inside each band.
Margins
| Q2 2026 | Q2 2025 | Change | |
|---|---|---|---|
| Free cash flow margin | 7.2% | 3.5% | +3.7 pts |
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Soft Tissue Repair Products | $25.2M | $22.7M | $2.6M | +11% |
| Bone Fusion Products | $2.9M | $3.1M | −$249K | -8% |
| Revenue | $28.1M | $25.8M | $2.3M | +9% |
| Net loss | $453K | $2.0M | −$1.6M | -78% |
| Costs & expenses | $28.6M | $27.8M | $767K | +3% |
| Operating costs | $26.4M | $23.3M | $3.0M | +13% |
| Interest & other, net | $2.2M | $4.5M | −$2.3M | -50% |
| Cost of revenue | $2.0M | $1.9M | $44K | +2% |
| Research & development | $1.2M | $1.1M | $97K | +9% |
| Sales & marketing | $16.9M | $15.7M | $1.2M | +8% |
| General & admin | $5.7M | $4.0M | $1.8M | +45% |
| Other operating costs | $619K | $689K | −$69K | -10% |
| Operating cash sources | $2.5M | $4.7M | −$2.2M | -47% |
| Depreciation & amortization | $619K | $1.1M | −$495K | -44% |
| Share-based compensation | $1.5M | $1.4M | $61K | +4% |
| Working capital & other | $376K | $2.1M | −$1.8M | -82% |
| Net loss absorbed | $453K | $2.0M | −$1.6M | -78% |
| Operating cash flow | $2.0M | $2.7M | −$626K | -23% |
| Free cash flow (OCF − capex) | $2.0M | $903K | $1.1M | +125% |
| Capital expenditures | $5K | $1.8M | −$1.8M | -100% |
Questions
How much did Sanara MedTech's revenue grow year over year in Q2 2026?
Sanara MedTech's revenue rose $2.3M (+9%) from $25.8M in Q2 2025 to $28.1M in Q2 2026.
What drove Sanara MedTech's revenue change in Q2 2026?
Soft Tissue Repair Products +$2.6M (+11%); Bone Fusion Products −$249K (-8%).